Bristol-Myers Squibb (BMY) Stock
Fundamentals
Recent news

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
BMY

Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
BMY

Why Women-Run Companies Deserve a Place in Your Portfolio
Why Women-Run Companies Deserve a Place in Your Portfolio
BMY

Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
BMY
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.70 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
BMY

Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
BMY

Why Women-Run Companies Deserve a Place in Your Portfolio
Why Women-Run Companies Deserve a Place in Your Portfolio
BMY

Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?
BMY

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
BMY

Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now?
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now?
BMY

New Strong Buy Stocks for September 24th
New Strong Buy Stocks for September 24th
BMY

Best Income Stocks to Buy for September 24th
Best Income Stocks to Buy for September 24th
BMY

4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout
4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout
BMY

BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
BMY
About Bristol-Myers Squibb
We are a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We work every day to transform patients’ lives through science. We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Christopher S. Boerner Ph.D. | CEO & Chairman | 1971 |
| Mr. David V. Elkins | Executive VP & CFO | 1968 |
| Mr. Greg Meyers | Executive VP and Chief Digital & Technology Officer | 1973 |
| Mr. Adam Lenkowsky | Executive VP & Chief Commercialization Officer | 1972 |
| Mr. Cristian Massacesi M.D. | Executive VP, Chief Medical Officer & Head of Development | 1969 |
| Ms. Karin Shanahan | Executive VP, Chief Supply Chain & Operations Officer | 1965 |
| Mr. Charles E. Triano | SVP & Head of Investor Relations | — |
| Ms. Cari Gallman | Executive VP, General Counsel & Chief Policy Officer | 1980 |
| Ms. Ahn Amanda Poole | Executive VP & Chief People Officer | 1975 |
| Dr. Joseph J. Eiden Jr. | Head of Medical Affairs | 1949 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
11 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -2.4 | -1.9 | -8.6 | +13.5 | ||||||||
| 2022 | +4.9 | +5.3 | +6.4 | +2.0 | +0.5 | +2.7 | -4.0 | -8.4 | +2.9 | +9.8 | +3.3 | -11.0 |
| 2023 | +0.5 | -3.2 | -0.1 | -4.2 | -5.8 | -1.1 | -3.5 | +0.2 | -6.4 | -10.9 | -3.7 | +2.4 |
| 2024 | -7.4 | +4.3 | +6.6 | -17.1 | -7.1 | -0.6 | +15.2 | +3.7 | +2.4 | +5.4 | +9.0 | -5.6 |
| 2025 | +3.8 | -0.6 | +1.9 | -15.7 | -2.7 | -5.1 | -8.8 | +6.7 | -4.9 | -2.9 | +6.9 | +9.7 |
| 2026 | +3.0 | +11.6 | -2.7 | -1.8 | -1.8 | +4.9 | +15.7 | +2.0 | -6.1 |



